INCYTE CORPORATION Investment Income, Interest
INCYTE CORPORATION (INCY) reported Investment Income, Interest of $33.69 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-04-28
- INCYTE CORPORATION investment income, interest for the quarter ending 2026-03-31 was $33.69M, a 46.92% increase year-over-year.
- INCYTE CORPORATION investment income, interest for the quarter ending 2025-12-31 was $30.75M, a 45.08% increase year-over-year.
- INCYTE CORPORATION investment income, interest for the quarter ending 2025-09-30 was $26.78M, a 39.01% increase year-over-year.
- INCYTE CORPORATION investment income, interest for the quarter ending 2025-06-30 was $25.14M, a 39.40% decline year-over-year.
- INCYTE CORPORATION investment income, interest for fiscal 2025 was $105.60M, a 17.96% decline from fiscal 2024.
- INCYTE CORPORATION investment income, interest for fiscal 2024 was $128.71M, a 18.75% decline from fiscal 2023.
- INCYTE CORPORATION investment income, interest for fiscal 2023 was $158.41M, a 291.62% increase from fiscal 2022.
- INCYTE CORPORATION investment income, interest for fiscal 2022 was $40.45M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-03-31 | $33.69M 10-Q · filed 2026-04-28 | $64.44M derived: sum of 2 quarters · filed 2026-04-28 | $91.22M derived: sum of 3 quarters · filed 2026-04-28 | $116.36M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $30.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $57.53M derived: sum of 2 quarters · filed 2026-02-10 | $82.67M derived: sum of 3 quarters · filed 2026-02-10 | $105.60M 10-K · filed 2026-02-10 |
| 2025-09-30 | $26.78M 10-Q · filed 2025-10-28 | $51.92M derived: sum of 2 quarters · filed 2025-10-28 | $74.85M 10-Q · filed 2025-10-28 | $96.04M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | $25.14M 10-Q · filed 2025-07-29 | $48.06M 10-Q · filed 2025-07-29 | $69.26M derived: sum of 3 quarters · filed 2026-04-28 | $88.53M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | $22.93M 10-Q · filed 2026-04-28 | $44.13M derived: sum of 2 quarters · filed 2026-04-28 | $63.39M derived: sum of 3 quarters · filed 2026-04-28 | $104.87M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $21.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $40.46M derived: sum of 2 quarters · filed 2026-02-10 | $81.94M derived: sum of 3 quarters · filed 2026-02-10 | $128.71M 10-K · filed 2026-02-10 |
| 2024-09-30 | $19.27M 10-Q · filed 2025-10-28 | $60.74M derived: sum of 2 quarters · filed 2025-10-28 | $107.51M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $41.48M 10-Q · filed 2025-07-29 | $88.25M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $46.77M 10-Q · filed 2025-04-29 | |||
| 2023-12-31 | $158.41M 10-K · filed 2026-02-10 | |||
| 2022-12-31 | $40.45M 10-K · filed 2025-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |